<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852021000200010</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v81i2.734</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Prostate-Specific Antigen (PSA) screening for Prostate Cancer (PCa): Main recommendations]]></article-title>
<article-title xml:lang="es"><![CDATA[Detección de antígeno prostático específico (PSA) para el cáncer de próstata (CaP): recomendaciones principales]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Perdomo]]></surname>
<given-names><![CDATA[Herney Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Valle Escuela de Medicina ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Valle Escuela de Medicina ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>81</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852021000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852021000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852021000200010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Prostate cancer is the most frequent type of cancer diagnosed in men and is the second cause of cancer death in the United States. The widespread use of Prostate-Specific Antigen since the early 1990s has significantly increased its incidence. However, screening for prostate cancer remains one of the most controversial topics in the urologic literature. The latest clinical evidence suggests that screening does not affect all-cause mortality and has only a small effect on prostate-specific mortality. At the same time, there are risks associated with biopsy and prostate cancer treatment, such as urinary incontinence, infection, and erectile dysfunction. Current recommendations propose shared decision-making with the patient but differ, with respect to the appropriate ages for screening, as well as follow-up screening intervals.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer de próstata es el tipo de cáncer más frecuente diagnosticado en los hombres. Específicamente en Estados Unidos, corresponde a la segunda causa de muerte por cáncer. El uso generalizado de antígeno prostático específico desde principios de la década de 1990 ha aumentado significativamente su incidencia. Sin embargo, el cribado del cáncer de próstata sigue siendo uno de los temas más controvertidos en la literatura urológica. La evidencia científica más reciente sugiere que el cribado no afecta la mortalidad por todas las causas y solo un pequeño efecto en la mortalidad específica de la próstata. Al mismo tiempo, existen riesgos asociados con la biopsia y el tratamiento del cáncer de próstata, como incontinencia urinaria, infección y disfunción eréctil. Las recomendaciones actuales proponen la toma de decisiones compartida con los hombres, aunque existen diferencias notables, especialmente en lo que respecta a las edades adecuadas de detección y los intervalos de seguimiento.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Prostate]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Prostate-specific antigen]]></kwd>
<kwd lng="en"><![CDATA[Screening]]></kwd>
<kwd lng="es"><![CDATA[Próstata]]></kwd>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[antígeno prostático específico]]></kwd>
<kwd lng="es"><![CDATA[tamizaje]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2018</year>
<volume>68</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>394-424</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics, 2020]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2020</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shenoy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Packianathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Vijayakumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do African-American men need separate prostate cancer screening guidelines?]]></article-title>
<source><![CDATA[BMC Urol]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of cancer in Colombia]]></article-title>
<source><![CDATA[Colomb Med]]></source>
<year>2018</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>09-12</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[KJL]]></given-names>
</name>
<name>
<surname><![CDATA[Del Mar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dickinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Glasziou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of incidental prostate cancer: A systematic review of autopsy studies]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2015</year>
<volume>137</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1749-57</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howlader]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SEER Cancer Statistics Review 1975-2017]]></article-title>
<source><![CDATA[Natl Cancer Inst]]></source>
<year>2019</year>
<page-range>2000-16</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schröder]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers and screening for prostate cancer]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2006</year>
<volume>17</volume>
<numero>^s10</numero>
<issue>^s10</issue>
<supplement>10</supplement>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[History of the discovery and clinical translation of prostate-specific antigen]]></article-title>
<source><![CDATA[Asian J Urol]]></source>
<year>2014</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Angelis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rittenhouse]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Mikolajczyk]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Blair Shamel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Semjonow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Twenty Years of PSA: From Prostate Antigen to Tumor Marker]]></article-title>
<source><![CDATA[Rev Urol]]></source>
<year>2007</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>113-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate Cancer Screening]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>2018</year>
<volume>102</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>199-214</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sikora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer screening]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2012</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Flite]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[State of the Art and Science. Electronic Health Records: Privacy, Confidentiality, and Security]]></article-title>
<source><![CDATA[Am Med Assoc J Ethics]]></source>
<year>2012</year>
<volume>14</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>712-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>Care CTF on PH</collab>
<source><![CDATA[Benefits and Harms of PSA Screening]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinsky]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Parnes]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Andriole]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality and Complications Following Prostate Biopsy in the PLCO Cancer Screening Trial]]></article-title>
<source><![CDATA[BJU]]></source>
<year>2014</year>
<volume>113</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>254-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Pauler]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tangen]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lucia]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Parnes]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2239-46</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ilic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Djulbegovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Cleves]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2018</year>
<volume>362</volume>
<page-range>k3519</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Curry]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Bibbins-Domingo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Caughey]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for prostate cancer USPreventive servicestaskforcerecommendation statement]]></article-title>
<source><![CDATA[JAMA - J Am Med Assoc]]></source>
<year>2018</year>
<volume>319</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1901-13</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mottet van den B]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Briers PC]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grummet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis FG]]></surname>
<given-names><![CDATA[Henry]]></given-names>
</name>
<name>
<surname><![CDATA[van der Kwast]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van der Poel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lam M]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[TWOR]]></surname>
<given-names><![CDATA[Tilki]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2019]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Van den Broeck MC]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Assoc Urol Guidel 2019]]></source>
<year>2019</year>
<volume>53</volume>
<page-range>1-161</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Albertsen]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Etzioni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Freedland]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early Detection Of Prostate Cancer: AUA Guideline]]></article-title>
<source><![CDATA[Am Urol Assoc Clin Guidel]]></source>
<year>2018</year>
<page-range>1-27</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[Peter R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kellog Parsons]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Andriole]]></surname>
<given-names><![CDATA[Gerald]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnson]]></surname>
<given-names><![CDATA[Robert R.]]></given-names>
</name>
<name>
<surname><![CDATA[EPC]]></surname>
<given-names><![CDATA[Sigrid Carlsson]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate Cancer Early Detection]]></source>
<year>2019</year>
<publisher-name><![CDATA[National Comprehensive Cancer Network]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
